“showed a trend”

This effect occurred because the intervention group scored significantly worse than the community group, p = 0.031, and the waitlist group showed a trend toward worse performance than the community group, p = 0.063.

The differences in the percentage of positive blood cultures at baseline and immediately after subgingival irrigation showed a trend to statistical significance ( p = 0.063).

There were no significant differences between RD patients and controls regarding baseline clinical characteristics, renal function, or antihypertensive treatment, although the control group showed a trend toward a higher rate of coronary artery disease (12 [52.2%] in RD patients versus 5 [100%] in controls, P =0.063).

Finally, within the Medalist group, history of CVD correlated weakly with neuropathy ( P = 0.01) and showed a trend with nephropathy ( P = 0.063) but not with PDR ( P = 0.1).

The abundance of unclassified Lachnospiraceae was increased in the ileum in Exp I (p = 0.007) and showed a trend towards increase in Exp III (p = 0.063, Fig 6d ).

Conversely, poor prognosis patients showed a trend towards higher levels of these two miRNAs than NET cell lines (miR‐17‐5p: H727 vs NENs, p = 0.063; BON‐1 vs NENs, p = 0.066; miR‐19a‐3p: H727 vs NENs, p = 0.085; BON‐1 vs NENs, p = 0.088).

After adjusting for baseline differences using IPTW, TEVAR showed a trend towards reduced mortality with an IPTW-adjusted hazard ratio (HR) of 0.53 [95% CI: 0.27–1.04, P = 0.063] (Fig. 6 a).

Although C-ACT scores showed a trend towards improvement (baseline: 22.5, study end: 24, p = 0.063), no significant change in lung function was observed.

Forest plot analysis showed that, when cytogenetic, genetic, and clinical criteria were analyzed separately, MR-cytogenetic alone (hazard ratio [HR], 5.76; 95% CI, 2.78-11.95; P < .001) and sM-AML alone (HR, 3.98; 95% CI, 1.10-14.46; P = .036) were significantly associated with inferior survival, whereas MR-molecular alone showed a trend toward worse outcome that did not reach statistical significance (HR, 1.97; 95% CI, 0.96-4.04; P = .063).

Non-PDAC pathology also showed a trend toward increased risk (OR: 1.88, 95% CI: 0.98–3.76, p = 0.063).

While the univariate analysis showed a trend toward statistical significance (OR = 0.854; p = 0.063), the multivariate model indicated that PMI was an independent factor associated with a complicated disease course (OR = 0.655; p = 0.018).

HMP showed a trend to lower DGF-rate in the marginal-matched comparison (9.2% vs. 16.1%, p = 0.063).

While our study showed a trend towards reduced amputation rates in the LSB group (0%) compared to the medical treatment group (23%), this difference did not reach statistical significance ( p = 0.063).

Kaplan–Meier analysis of the AML patients showed a trend toward worse prognosis among patients exhibiting above-median IQGAP1 expression ( p = 0.063) (Fig. 1 H).

Among these groups, SUV mean showed a trend of increasing values (G1, SUVmean = 5.04 ± 0.7; G2, SUV mean = 6.65 ± 0.91; G3, SUV mean = 7.04 ± 1.07; P = 0.063).

Notably, AKI scores showed a trend toward a significant reduction in the subgroup ( P = 0.063).

BMP4 and BMP6 also showed a trend of increased Ki67 mRNA (P = 0.063 and 0.052, respectively).

Clinical factors such as muscular weakness (OR = 0.485, 95% CI: 0.239–0.987, p = 0.046) and heliotropic rash (OR = 0.426, 95% CI: 0.207–0.877, p = 0.021) were associated with reduced odds, while fever showed a trend toward increased odds (OR = 2.579, 95% CI: 0.949–7.008, p = 0.063).

While combination ICI with chemotherapy showed a trend toward increased risk (HR: 1.664; 95% CI: 0.974–2.848; p = 0.063), and ICI monotherapy showed a trend toward reduced risk (HR: 0.613; 95% CI: 0.352–1.062; p = 0.082), these findings did not reach statistical significance.

PD-L1 expression ≥ 1% showed a trend toward improved OS (HR 3.72, p = 0.063).

ERN-LFPs were significantly more negative than CRN-LFPs bilaterally in P2 and P4 and showed a trend level difference in the right NAc in P1 (P1 right p = 0.063; P2 and P4 p >0.002; Table 3 ; Figure 3 ).

For tumors 5–10 cm, chemotherapy showed a trend toward improved survival (HR = 0.45, 95% CI: 0.19–1.05, p = 0.063).

As a matter of fact, subjects with a baseline-impaired DLCO (<80% pred at T0; n = 38) showed a trend in improvement at 6 months ( p = 0.063).

TAR also showed a trend toward protection in adjusted analysis (HR, 0.381, 95% CI, 0.138-1.053, P = .063).

In the present study, univariate analysis showed a trend toward an association between Hp infection and disease progression (74% in the progressive group vs. 54% in the stable group, P = 0.063), although it did not reach statistical significance.